Cargando…
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
The SRC family kinase (SFK) HCK is transcriptionally upregulated and activated by mutated MYD88 (MYD88(Mut)), a key adaptor for Toll-receptor signaling. HCK activates BTK, AKT, and ERK in MYD88(Mut) lymphomas. SYK, a B-cell receptor (BCR) component, is activated in MYD88(Mut) lymphoma cells. Althoug...
Autores principales: | Munshi, Manit, Liu, Xia, Kofides, Amanda, Tsakmaklis, Nickolas, Guerrera, Maria Luisa, Hunter, Zachary R., Palomba, M. Lia, Argyropoulos, Kimon V., Patterson, Christopher J., Canning, Alexa G., Meid, Kirsten, Gustine, Joshua, Branagan, Andrew R., Flynn, Catherine A., Sarosiek, Shayna, Castillo, Jorge J., Wang, Jinhua, Buhrlage, Sara J., Gray, Nathanael S., Munshi, Nikhil C., Anderson, Kenneth C., Treon, Steven P., Yang, Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198919/ https://www.ncbi.nlm.nih.gov/pubmed/35255496 http://dx.doi.org/10.1182/bloodadvances.2021006147 |
Ejemplares similares
-
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020) -
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021) -
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
por: Castillo, Jorge J., et al.
Publicado: (2022) -
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
por: Gustine, Joshua N., et al.
Publicado: (2021) -
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2021)